ImCheck HP

Exploring uncharted territories in immunomodulation
Butyrophilins & Gamma-delta T cells

ImCheck Therapeutics is driving innovation in immune system modulation based on our unique know-how in the butyrophilin (BTN) and BTN-like (BTNL) superfamily of checkpoint molecules. We are designing the next generation of immunotherapeutic antibodies for the treatment of cancer, infectious disease, and autoimmune disease.

Latest news


ImCheck selected as laureate of the new French Tech 2030 program
Leadership & Corporate 
Read more
ImCheck Achieves the Primary Objectives of Phase I of the EVICTION-2 Trial of ICT01 in Combination with Low Dose IL-2, Data Presented at AACR 2023
Science & Medicine 
Read more
ImCheck Appoints Thomas Civik as Independent Chairman of the Board
Leadership & Corporate 
Read more

Festival of Biologics

From  Oct 10, 2023  to  Oct 12, 2023 

Read more

ESMO 2023

From  Oct 20, 2023  to  Oct 24, 2023 

Read more

SITC 2023

From  Nov 01, 2023  to  Nov 05, 2023 

Read more

STAY IN TOUCH WITH OUR LATEST NEWS

Subscribe to receive our press releases and related news